Arcutis Biotherapeutics Inc
ARQT
NASDAQ
Biotechnology
$26.19
USD
+0.36 (+1.39%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.25B
Volume 1.1M
Revenue
$463.98M
TTM
+76.1%
YoY
Gross Margin
91%
TTM
+2.3%
YoY
Net Income
$28.52M
TTM
+130.6%
YoY
Operating Cash Flow
$39.31M
TTM
+160.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 81.5 | 99.2 | 129.5 | 105.4 | 129.9 |
YoY Growth | +164.1% | +121.7% | +81.5% | +60.1% | +59.3% |
Cost of Revenue | 7.5 | 8.7 | 11.7 | 9.8 | 10.9 |
Gross Profit | 74.0 | 90.5 | 117.8 | 95.6 | 118.9 |
Selling, General & Administrative | 69.2 | 62.4 | 79.0 | 74.1 | 82.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 88.6 | 82.0 | 99.4 | 104.7 | 102.5 |
Operating Income | -14.6 | 8.5 | 18.4 | -9.1 | 16.4 |
EBITDA | -17.6 | 9.1 | 14.3 | -8.5 | 15.9 |
Other Income / Expense | 0.0 | 2.0 | -6.4 | -0.0 | -0.2 |
Total Other Income / Expense | -0.9 | -1.0 | -0.5 | -2.1 | -1.3 |
Income Before Income Taxes | -15.5 | 7.5 | 17.9 | -11.2 | 15.1 |
Income Taxes | 0.3 | 0.1 | 0.5 | 0.1 | 0.1 |
Net Income | -15.9 | 7.4 | 17.4 | -11.3 | 15.0 |
Consolidated Net Income / Loss | -15.9 | 7.4 | 17.4 | -11.3 | 15.0 |
Net Income Attributable to Common Shareholders | -15.9 | 7.4 | 17.4 | -11.3 | 15.0 |
Basic EPS | -$0.13 | $0.06 | $0.14 | -$0.09 | $0.11 |
Diluted EPS | -$0.13 | $0.06 | $0.14 | -$0.09 | $0.11 |
Basic Shares Outstanding | 127.0M | 127.6M | 128.3M | 129.4M | 130.5M |
Diluted Shares Outstanding | 127.0M | 132.9M | 123.0M | 129.4M | 135.9M |